Analysts have turned cautious on Cipla, as the recently issued form 483 by the US FDA with eight observations to its Pithampur (Indore) plant is expected to delay the launch of the company’s key generic – Advair – in the US. The Indore plant contributes around 5 per cent of Cipla’s revenues, as per analysts’ estimates. While the respiratory product, which is used to treat asthma, had cleared the pre-approval inspection of the regulator at the Indore unit; the final approval could be unlikely until the company clears the recent US FDA observations, analysts say.
| Subscribe To Our Free Newsletter |
